Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China

Trial Profile

Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2013

At a glance

  • Drugs Meningococcal vaccine groups A and C polysaccharide (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top